Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

[11C]Methylated LY2181308

In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004.
[updated ].
Affiliations
Free Books & Documents
Review

[11C]Methylated LY2181308

Kam Leung.
Free Books & Documents

Excerpt

Survivin is a small protein (142 amino acids, 16.5 kDa) that belongs to the inhibitor of apoptosis protein (IAP) family (1). IAPs can effectively suppress apoptosis induced by a variety of stimuli, including death receptor activation, growth factor withdrawal, ionizing radiation, viral infection, and genotoxic damage. Survivin comprises a single baculovirus IAP repeat domain and an extended COOH-terminal α-helical coiled-coil domain but lacks the RING-finger domain found in other IAPs. In addition to suppressing apoptosis, survivin is involved in many essential cellular functions, such as cell division, cell stress response, and surveillance checkpoints. Survivin is strongly expressed in the majority of human tumor types (2). As a new target in cancer treatment, inhibition of survivin expression can be carried out through the use of anti-sense oligonucleotides, ribozymes, and small interfering RNA (3). LY2181308 is an 18-mer survivin anti-sense oligonucleotide (6.8 kDa) against survivin mRNA (4, 5). Dence et al. (6) developed a rapid method for randomly 11C-methylated LY2181308 ([11C]LY2181308) for positron emission tomography (PET) imaging of survivin mRNA expression in tumors.

PubMed Disclaimer

Similar articles

References

    1. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. . Expert Opin Ther Targets. 2008;12(4):463–76. - PubMed
    1. Zaffaroni N., Pennati M., Daidone M.G. Survivin as a target for new anticancer interventions. . J Cell Mol Med. 2005;9(2):360–72. - PMC - PubMed
    1. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. . Cancer Treat Rev. 2009;35(7):553–62. - PubMed
    1. Carrasco, R.A., N.B. Stamm, E.G. Marcusson, G.E. Sandusky, P. Iversen, and B.K. Patel, Antisense Inhibition of Survivin Expression as a Cancer Therapeutic. Mol Cancer Ther, 2011 - PubMed
    1. Rodel F., Frey B., Leitmann W., Capalbo G., Weiss C., Rodel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. . Int J Radiat Oncol Biol Phys. 2008;71(1):247–55. - PubMed

LinkOut - more resources